Probi's Annual Report and Sustainability Report for 2022 are now available on the company website, www.probi.com under Investor Relations: https://www.probi.com/investor-relations/financial-reports/
This information is information that Probi AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 10.00 CET on 4 April 2023.
For further information, please contact:
Henrik Lundkvist, CFO, Probi, Phone +46 46 286 89 41, E-mail: henrik.lundkvist@probi.com
ABOUT PROBI
Probi[®] is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.
This information was distributed by Cision http://www.cisionwire.se/